scholarly journals Naturopathic Management of Females with Cervical Atypia: A Delphi Process to Explore Current Practice

2013 ◽  
Vol 8 ◽  
pp. IMI.S11088 ◽  
Author(s):  
Cynthia Ann Leaver ◽  
Claiborne Miller-Davis ◽  
Gwenyth R. Wallen
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Health Behavior ◽  
Cervical Cancer Screening ◽  
Green Tea ◽  
Delphi Study ◽  
Behavior Management ◽  
Integrative Approach ◽  
Screening Guidelines ◽  
Systemic Treatments

Background Human papillomavirus is the most significant factor contributing to cervical cancer. Naturopathic doctors (NDs) implement an integrative approach to treat cervical atypia. This study explored practice consensus and variance among NDs. Methods A purposefully selected panel of six NDs participated in a modified Delphi study to validate practice. Three electronic web-based surveys were completed over nine months. Results Local and systemic treatments were included in all ND protocols. Six protocols included cervical cancer screening guidelines, green tea suppositories, and oral folic acid. Five protocols included oral green tea, diindoylemethane (DIM), and cartenoids. Four protocols incorporated Vitamin C. Two NDs considered escharotics when managing cervical atypia. All NDs included health behavior management in their protocols. Conclusion Naturopathic management of cervical atypia varies across practitioners. However, in general, elements of management include (1) cervical cancer screening guidelines, (2) local and systemic treatments, (3) health behavior/lifestyle recommendations, and (4) immune system support.

The application of health behavior theories to promote cervical cancer screening uptake

2021 ◽  
Author(s):  
Jyoshma Preema Dsouza ◽  
Stephan Van den Broucke ◽  
Sanjay Pattanshetty ◽  
William Dhoore
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Health Behavior ◽  
Cervical Cancer Screening ◽  
Screening Uptake ◽  
Behavior Theories

scholarly journals Recent changes in cervical cancer screening guidelines: U.S. women's willingness for HPV testing instead of Pap testing

2020 ◽  
Vol 130 ◽  
pp. 105928
Author(s):  
Erika L. Thompson ◽  
Annalynn M. Galvin ◽  
Ellen M. Daley ◽  
Ovidiu Tatar ◽  
Gregory D. Zimet ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Hpv Testing ◽  
Pap Testing ◽  
Screening Guidelines

Assessing Cervical Cancer Screening Guidelines in Patient Education Materials

2009 ◽  
Vol 18 (1) ◽  
pp. 5-12 ◽  
Author(s):  
Katherine B. Roland ◽  
Vicki B. Benard ◽  
Mona Saraiya ◽  
Nikki A. Hawkins ◽  
Heather Brandt ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Patient Education ◽  
Cervical Cancer Screening ◽  
Screening Guidelines

Dynamics of Human Papillomavirus and Cervical Cancer Screening

2011 ◽  
Vol 07 (04) ◽  
pp. 243
Author(s):  
Channa E Schmeink ◽  
Leon FAG Massuger ◽  
Willem JG Melchers ◽  
Ruud LM Bekkers ◽  
◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Cervical Carcinoma ◽  
Participation Rate ◽  
Productive Infection ◽  
High Grade ◽  
Screening Guidelines ◽  
Hpv Test

Primary screening based on detection of human papillomavirus (HPV) has proved to be more sensitive than cytology for the detection of high-grade cervical intraepithelial neoplasia (CIN). Self-sampling for specimen collection may also improve the participation rate, especially in the non-responder group. However, HPV is highly prevalent and therefore HPV detection has a lower specificity in cervical cancer screening than cytology. In addition to the clinically validated HPV test, HPV dynamics should be taken into account. It is important to identify women with a chronic productive infection likely to cause, or to already have caused, high-grade CIN or cervical carcinoma, and to limit overtreatment of women with a transient infection. Furthermore, the introduction of the HPV vaccine is likely to lower the incidence of CIN and cervical carcinoma, which will lower the positive predictive value of cervical cancer screening. This potential impact needs to be taken into account when planning for future screening guidelines.

scholarly journals Improving Compliance with Cervical Cancer Screening Guidelines

2015 ◽  
Vol 28 (4) ◽  
pp. 450-453 ◽  
Author(s):  
Jessica Langsjoen ◽  
Cara Goodell ◽  
Eduardo Castro ◽  
Jen Thomas ◽  
Thomas J. Kuehl ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Screening Guidelines

scholarly journals State of the Science: Screening, Surveillance, and Epidemiology of HPV-Related Malignancies

2021 ◽  
pp. 1-12
Author(s):  
Rahel Ghebre ◽  
J. Michael Berry-Lawhorn ◽  
Gypsyamber D’Souza
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Resolution ◽  
Cervical Cancer Screening ◽  
Task Force ◽  
Hpv Vaccination ◽  
Cancer Society ◽  
Screening Guidelines ◽  
Cancer Precursors ◽  
The U.S

Oropharyngeal, cervical, vulvar, and anal cancers share a common risk factor of HPV infection. HPV vaccination is currently recommended at age 11 or 12 to prevent new HPV infections for all genders with catch-up vaccination recommened up to age 26. Despite the known effectiveness of HPV vaccination to prevent HPV-related cancer, there is continued low uptake in the United States; only 40% of eligible persons were vaccinated in 2018, though rates are 70% among teenagers. Current American Cancer Society cancer screening guidelines recommend cervical cancer screening, but do not have specific recommendations for screening for other HPV-related cancers. Oropharyngeal cancer precursors have yet to be identified, and there are currently no routine screening tests for oropharyngeal cancer recommended by the U.S. Preventive Services Task Force. The U.S. Preventive Services Task Force and American Cancer Society recommend cervical cancer screening for women at average risk up to age 65, and screening guidelines do not currently differ by HPV vaccination status. Primary HPV DNA testing was first approved for cervical cancer screening in 2016 and was shown to be superior for cervical cancer prevention. Vulvar and anal cancer precursors have been identified, but optimal screening remains unclear. Examination of the anal canal and perianus is best performed by trained clinicians using high-resolution anoscopy, and effectiveness of using high-resolution anoscopy to detect and treat anal high-grade squamous intraepithelial lesions to prevent cancer is actively being researched. Current multistep approaches to control HPV-related malignancies include HPV vaccination coupled with cervical cancer screening or surveillance for oropharyngeal, vulvar, and anal cancers.

Sign in / Sign up

Export Citation Format

Share Document